



**FOR IMMEDIATE RELEASE**

June 22, 2009

**CONTACT: SHAWN MCGREEVY**

smcgreevy@bellpharm.com  
612.721.3976 (office) 612.203.6953 (cell)

**BELL PHARMACEUTICALS, INC. ANNOUNCES  
JET-ALERT PRODUCT PARTICIPATION IN NEW STUDY**

*Will Identify and Validate a Probe Cocktail for Use in Future Drug-Drug Interaction Studies*

**MINNEAPOLIS, MINNESOTA:** Bell Pharmaceuticals announced today that its JET-ALERT 100mg caffeine tablet product is now being used as primary standard by GlaxoSmithKline in a Validation Study of Simultaneous Administration of Multiple Cytochrome P450/Transporter Probes for Drug Interaction Evaluation in Healthy Adult Subjects. The purpose of this study is to identify and validate a probe cocktail for use in future drug-drug interaction studies. Cytochrome P450 enzymes and transport proteins play important roles in the disposition of drugs.

*Caffeine as CYP1A2 Probe:* Caffeine is almost completely absorbed following oral administration with peak plasma levels occurring within 30 to 60 minutes and a terminal half – life of 4 to 5 hours [Kaplan 1997]. Caffeine is a well-accepted probe for CYP1A2 [Huang, 2007; Fuhr, 2007] and has been used in more than 30 published clinical drug interaction studies [University of Washington, 2008].

**Cosmetic Division**  
4525 Hiawatha Avenue S.  
Minneapolis, MN 55406  
Tel 612.721.3976  
Fax 612.724.5002

**Pharmaceutical Division**  
200 W. Beaver Street  
Belle Plaine, MN 56011  
Tel 952.873.2288  
Fax 952.873.2289

**EPA/Packaging Division**  
2740 E. 27<sup>th</sup> Street  
Minneapolis, MN 55406  
Tel 612.721.1662  
Fax 612.721.8703